Current Issue June 2012, Vol. 22, No. 6

Issue Highlights

Review

Antipsychotic medication and prefrontal cortex activation: A review of neuroimaging findings

Research Paper

Hematological clozapine monitoring with a point-of-care device: A randomized cross-over trial

European Neuropsychopharmacology News

The Size and Burden of Mental Disorders and Other Disorders of the Brain in Europe – It’s worse than we thought
5 September 2011

Funding crisis threatens development of new treatments for mental illness – urgent action needed
4 September 2011

Chronic effects of corticosterone on GIRK1-3 subunits and 5-HT1A receptor expression in rat brain and their reversal by concurrent fluoxetine treatment
17 May 2012
Laura Saenz del Burgo, Roser Cortés, Guadalupe Mengod, Mario Montaña, Gontzal García del Caño, Joan Sallés
Abstract: Dysregulation of the serotonergic system and abnormalities of the hypothalamic–pituitary–adrenal axis have been demonstrated in major depression. Animal studies indicate that 5-HT1A receptor...
Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis
16 May 2012
Oswald J.N. Bloemen, Mariken B. de Koning, Tobias Gleich, Julia Meijer, Lieuwe de Haan, Don H. Linszen, Jan Booij, Thérèse A.M.J. van Amelsvoort
Abstract: Altered striatal dopaminergic neurotransmission is thought to be fundamental to schizophrenia. Increased presynaptic dopaminergic activity ([18F]–DOPA PET) may predate the onset of psychotic...
Testosterone in the brain: Neuroimaging findings and the potential role for neuropsychopharmacology
14 May 2012
Peter Höfer, Rupert Lanzenberger, Siegfried Kasper
Abstract: Testosterone plays a substantial role in a number of physiological processes in the brain. It is able to modulate the expression of certain genes by binding to androgen receptors. Acting via...
Operant behavior to obtain palatable food modifies ERK activity in the brain reward circuit
14 May 2012
Thomas Guegan, Laura Cutando, Giuseppe Gangarossa, Emanuela Santini, Gilberto Fisone, Albert Martinez, Emmanuel Valjent, Rafael Maldonado, Miquel Martin
Abstract: Food palatability produces behavioral modifications that resemble those induced by drugs of abuse. Palatability-induced behavioral changes require both, the activation of the endogenous cann...
Patients' acceptance of the deltoid application of risperidone long-acting injection
14 May 2012
Stephan Heres, Teresa Frobose, Johannes Hamann, Stefan Leucht, Katja Maino, Tatjana Reichhart, Michaela Stiegler, Werner Kissling
Abstract: Objective: Recently risperidone long-acting injection (RLAI) was approved for alternative injection into the deltoid muscle in addition to the already established injection into the gluteal ...

View More Articles in Press...

Cost of disorders of the brain in Europe 2010
October 2011 (Vol. 21 | No. 10 | Pages 718-779)
Anders Gustavsson, Mikael Svensson, Frank Jacobi, Christer Allgulander, Jordi Alonso, Ettore Beghi, Richard Dodel, Mattias Ekman, Carlo Faravelli, Laura Fratiglioni, Brenda Gannon, David Hilton Jones, Poul Jennum, Albena Jordanova, Linus Jönsson, Korinna Karampampa, Martin Knapp, Gisela Kobelt, Tobias Kurth, Roselind Lieb, Mattias Linde, Christina Ljungcrantz, Andreas Maercker, Beatrice Melin, Massimo Moscarelli, Amir Musayev, Fiona Norwood, Martin Preisig, Maura Pugliatti, Juergen Rehm, Luis Salvador-Carulla, Brigitte Schlehofer, Roland Simon, Hans-Christoph Steinhausen, Lars Jacob Stovner, Jean-Michel Vallat, Peter Van den Bergh, Jim van Os, Pieter Vos, Weili Xu, Hans-Ulrich Wittchen, Bengt Jönsson, Jes Olesen, on behalf of the CDBE2010 study group
Corrigendum to “Cost of disorders of the brain in Europe 2010” [Eur. Neuropsychopharmacol. 21 (2011) 718–779]
March 2012 (Vol. 22 | No. 3 | Pages 237-238)
Anders Gustavsson, Mikael Svensson, Frank Jacobi, Christer Allgulander, Jordi Alonso, Ettore Beghi, Richard Dodel, Mattias Ekman, Carlo Faravelli, Laura Fratiglioni, Brenda Gannon, David Hilton Jones, Poul Jennum, Albena Jordanova, Linus Jönsson, Korinna Karampampa, Martin Knapp, Gisela Kobelt, Tobias Kurth, Roselind Lieb, Mattias Linde, Christina Ljungcrantz, Andreas Maercker, Beatrice Melin, Massimo Moscarelli, Amir Musayev, Fiona Norwood, Martin Preisig, Maura Pugliatti, Juergen Rehm, Luis Salvador-Carulla, Brigitte Schlehofer, Roland Simon, Hans-Christoph Steinhausen, Lars Jacob Stovner, Jean-Michel Vallat, Peter Van den Bergh, Jim van Os, Pieter E. Vos, Weili Xu, Hans-Ulrich Wittchen, Bengt Jönsson, Jes Olesen, on behalf of the CDBE2010 study group
- Full Text
- PDF (127 KB)
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy
April 2012 (Vol. 22 | No. 4 | Pages 239-258)
Stefano Porcelli, Chiara Fabbri, Alessandro Serretti
Corrigendum to “Omega-3 fatty acids in major depressive disorder A preliminary double-blind, placebo-controlled trial” [Eur. Neuropsychoparmacol. 13 (2003) 267–271]
March 2004 (Vol. 14 | No. 2 | Page 173)
Kuan-Pin Su, Shih-Yi Huang, Chi-Chiang Chiu, Winston W. Shen
- Full Text
- PDF (47 KB)

Most Read lists are compiled every quarter.

New Issue Alert

Free Trial Issue

About the Journal

European Neuropsycho-
pharmacology, the official journal of the European College of Neuropsychopharmacology (ECNP), publishes articles in the field of neuropsychopharmacology, its scope encompasses clinical and basic research relevant to the effects of centrally acting agents in its broadest sense.

More

Journal Ranking

Impact Factor: 4.201

Psychiatry: 22nd out of 126
Clinical Neurology: 30th out of 185
Pharmacology and Pharmacy: 38th out of 249
Neurosciences: 60th out of 237

Publishing Information

European Neuropsychopharmacology is published by Elsevier.

Access this journal onSciVerse ScienceDirect

Featured Webcast

ECNP Talk of the month
René Kahn
Schizophrenia

View More Webcasts

Journal Access

European Neuropsychopharmacology is available online. Abstracts and tables of contents are free to all viewers. Access to full-text articles is free to individual subscribers and ENCP members who will first need to register and claim access (link below).

Activate Online Access

About ECNP

ECNP is a pan-European scientific association in the field of neuropsychopharmacology. Established in 1987 to promote high-quality experimental and clinical research in neuropsychopharmacology, ECNP has become one of Europe's pre—eminent interdisciplinary platforms for the exchange and dissemination of scientific research on the brain and brain disorders.

ECNP is a non-profit member-based association, independently governed and self-funded.

More
ECNP Calendar of Events

25^th ECNP Congress

25^th ECNP Congress
13 - 17 October 2012
Vienna, Austria

More Information